Under construction – not a live service
Sign in
Taking people in ChinaPhase 3

Eloralintide weight loss study for adults with excess weight and type 2 diabetes

Tests eloralintide against placebo for weight loss in adults with type 2 diabetes.

Key facts

Who runs it
Eli Lilly and Company
Where
Beijing, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Luoyang Shi, Nanchang, Nanjing, Shanghai, Tianjin, and Zigong, ChinaSee the 16 sitesAlso in 12 other countries, 127 sites
Trial code
Registry title
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Status
Recruiting
Phase
Phase 3
People taking part
1,035 people, planned
Started
15 Dec 2025
Expected to end
Feb 2028
Type of study
Interventional, 5 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Eloralintide
  • Placebo
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes and a BMI of 27 kg/m2 or more. It compares eloralintide with placebo for weight loss.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Type 2 diabetes with overweight or obesity (BMI ≥ 27 kg/m2).
Earlier treatment
Must be on stable treatment for type 2 diabetes for at least 90 days before screening. Must not have taken amylin analogs, GLP-1 receptor agonists, GIP/GLP receptor agonists or insulin, or weight-loss medicines or remedies, within 90 days before screening.

Main reasons for not taking part

  • Type 1 diabetes
  • Prior or planned surgery, endoscopic procedure or device-based therapy for obesity (some exceptions apply)
  • Heart attack, stroke, coronary artery revascularization, unstable angina or hospitalization for heart failure within 90 days before screening
  • Class IV congestive heart failure (New York Heart Association)
  • Body weight change of 5% or more in the 90 days before screening

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Have type 2 diabetes
  • Are on stable treatment for type 2 diabetes for at least 90 days prior to screening
  • Have a BMI ≥ 27 kg/m2
  • Have a stable body weight (<5% body weight change) for 90 days prior to screening

Who cannot take part

  • Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
  • Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
  • Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure
  • Have taken medications or alternative remedies intended for weight loss within 90 days of screening
  • Have type 1 diabetes
  • Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
  • Have taken any of the following antihyperglycemic medications within 90 days before screening:; amylin analogs; glucagon-like peptide-1 (GLP-1) receptor agonists; glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP) receptor agonists, or; insulin

Where in China

Also in 12 other countries, 127 sites

  • Beijing Pinggu District HospitalBeijing, ChinaContact: yufeng li (principal investigator)Taking people
  • Luhe HospitalBeijing, ChinaContact: Dong Zhao (principal investigator)Taking people
  • Peking University People's HospitalBeijing, ChinaContact: Linong Ji (principal investigator)Taking people
  • Sichuan Provincial People's HospitalChengdu, ChinaContact: Limin Tian (principal investigator)Taking people
  • The Second Affiliated Hospital Chongqing Medical UniversityChongqing, ChinaContact: Dongfang Liu (principal investigator)Taking people
  • Zhujiang HospitalGuangzhou, ChinaContact: Jia Sun (principal investigator)Taking people
  • The Second People's Hospital of HefeiHefei, ChinaContact: Jun Ye (principal investigator)Taking people
  • Jinan Central HospitalJinan, ChinaContact: Nianrong Mi (principal investigator)Taking people
  • The First Affiliated Hospital of Henan University of Science &TechnologyLuoyang Shi, ChinaContact: Hongwei Jiang (principal investigator)Taking people
  • Jiangxi Provincial People's HospitalNanchang, ChinaContact: Zongyou Cheng (principal investigator)Taking people
  • Jiangsu Province Official HospitalNanjing, ChinaContact: Wei Tang (principal investigator)Taking people
  • Nanjing First HospitalNanjing, ChinaContact: Qian Li (principal investigator)Taking people
  • The Second Affiliated Hospital of Nanjing Medical UniversityNanjing, ChinaContact: Yibing Lu (principal investigator)Taking people
  • Jiading District Central HospitalShanghai, ChinaContact: Lixia Suo (principal investigator)Taking people
  • The Second Hospital of Tianjin Medical UniversityTianjin, ChinaContact: Yu Chen (principal investigator)Taking people
  • Zigong First People's HospitalZigong, ChinaContact: Jian Li (principal investigator)Taking people

About the trial

What the trial wants to find out

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

The 5 groups in the trial

  • Eloralintide Dose 1Treatment being tested

    Participants will receive eloralintide subcutaneously (SC)

    Treatment: Eloralintide

  • Eloralintide Dose 2Treatment being tested

    Participants will receive eloralintide SC

    Treatment: Eloralintide

  • Eloralintide Dose 3Treatment being tested

    Participants will receive eloralintide SC

    Treatment: Eloralintide

  • Eloralintide Dose 4Treatment being tested

    Participants will receive eloralintide SC

    Treatment: Eloralintide

  • PlaceboPlacebo, for comparison

    Participants will receive placebo SC

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes
Plain-language title
Eloralintide weight loss study for adults with excess weight and type 2 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
4 November 2026